Abstract
Purpose
The incidence of cervical cancer, including squamous cell carcinoma (SCC), has been decreasing in several developed countries since the onset of organized screening programs; in some countries, however, the incidence of adenocarcinoma has increased among young women. We investigated the Danish incidence trends during 1997–2011 when cervical screening coverage was high. Incidences of cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) were also assessed, with the latest part of the study period coinciding with introduction of free-of-charge human papillomavirus (HPV) vaccination.
Methods
Using nationwide registries, we estimated age-specific and age-standardized incidence rates and estimated annual percentage change (EAPC).
Results
The incidence of SCC decreased significantly, especially in women aged ≥45 years [EAPC: −3.1 % (95 % CI −4.3 to −2.5)], whereas the incidence of adenocarcinoma increased significantly, from 2.4 to 3.1/100,000 primarily due to increases in women aged ≤44 years [EAPC: 4.3 % (95 % CI 1.8–6.7)]. The incidences of CIN3 and AIS increased significantly from 94.7 to 156.5/100,000 and 3.3 to 11.3/100,000, respectively, but, importantly, they decreased significantly during 2009–2012 in women aged ≤20 years.
Conclusions
The Danish screening program has successfully reduced the incidence of cervical cancer, especially of SCC in older women; however, the program has not significantly reduced the incidence in young women or the incidence of adenocarcinoma, which is increasing. Decreases in the incidences of CIN3 and AIS in age groups with high HPV vaccine coverage may herald a future decrease in cervical cancer incidence in young Danish women.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality WORLDWIDE: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed August 2014
Seoud M, Tjalma WA, Ronsse V (2011) Cervical adenocarcinoma: moving towards better prevention. Vaccine 29:9148–9158. doi:10.1016/j.vaccine.2011.09.115
Adegoke O, Kulasingam S, Virnig B (2012) Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 21:1031–1037. doi:10.1089/jwh.2011.3385
Bray F, Loos AH, McCarron P et al (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomark Prev 14:677–686
Kyndi M, Frederiksen K, Kruger KS (2006) Cervical cancer incidence in Denmark over six decades (1943–2002). Acta Obstet Gynecol Scand 85:106–111
Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E (2004) Increasing trends of cervical adenocarcinoma incidence in Central Italy despite extensive screening programme, 1985–2000. Cancer Detect Prev 28:461–464
Zhu C, Bassig BA, Zhang Y et al (2014) A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA. Eur J Cancer Prev. doi:10.1097/CEJ.0000000000000062
Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A (2009) Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 20:1129–1138. doi:10.1007/s10552-009-9317-z
de Kok IM, van der Aa MA, van Ballegooijen M et al (2011) Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 128:2174–2181. doi:10.1002/ijc.25553
Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM (2007) Decreasing incidence of cervical adenocarcinoma in Ontario: this related to improved endocervical Pap test sampling? Int J Cancer 120:362–367
Sigurdsson K (1999) The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78:478–485
Lynge E (2002) Cervical cancer screening. Ugeskr Laeger 164:171–173
The Danish National Board of Health (2012) Screening for livmoderhalskræft–anbefalinger 2012 https://sundhedsstyrelsen.dk/publ/Publ2012/SYB/Kraeft/ScreenLivmoderhalskrftAnbef.pdf. Accessed October 2014
Stanley M (2010) Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117:S5–S10. doi:10.1016/j.ygyno.2010.01.024
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907
Moscicki AB, Schiffman M, Burchell A et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24–F33. doi:10.1016/j.vaccine.2012.05.089
Nøhr B, Frydshou D, Nielsen K, Fuglsang K, Hansen K, et al (2012) DSOG Kliniske Guidelines Udredning, behandling og kontrol af cervikal dysplasi (Danish Society of Obstetrics and Gynaecology). http://gynobsguideline.dk/hindsgavl/Cervixdysplasi2012.pdf. Accessed May 2014
Barken SS, Rebolj M, Andersen ES, Lynge E (2012) Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 130:2438–2444. doi:10.1002/ijc.26248
European Medicines Agency (2010) European public assessment report for Gardasil. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp. Accessed May 2014
Sander BB, Rebolj M, Valentiner-Branth P, Lynge E (2012) Introduction of human papillomavirus vaccination in Nordic Countries. Vaccine 30:1425–1433. doi:10.1016/j.vaccine.2011.11.097
Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632
Castellsague X, Diaz M, de Sanjosé S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303–315
Pimenta JM, Galindo C, Jenkins D, Taylor SM (2013) Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 13:553. doi:10.1186/1471-2407-13-553
Garland SM, Smith JS (2010) Human papillomavirus vaccines: current status and future prospects. Drugs 70:1079–1098. doi:10.2165/10898580-000000000-00000
Kjaer SK, Munk C, Junge J, Iftner T (2014) Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 25:179–189. doi:10.1007/s10552-013-0320-z
Statens Serum Institut (2013) EPI-NYT: HPV-vaccination-tilslutning 2012. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2013/Uge%2020%20-%202013.aspx?p=1. Accessed May 2014
Statens Serums Institut (2014) Epi-nyt uge 47, Vaccinationstilslutning i det midlertidige HPV-vaccinationsprogram til kvinder født 1985–1992. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2014/Uge%2047%20-%202014.aspx. Accessed November 2014
Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK (2014) Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25:915–922. doi:10.1007/s10552-014-0392-4
Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014) Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst 106: djt460. doi: 10.1093/jnci/djt460
Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39:42–45. doi:10.1177/1403494810393562
The Danish Pathology Data Bank (2011). http://www.patobank.dk/. Accessed May 2014
Statens Serum Institut (2013) Indberetning og patientregistrering: Patologi. http://www.ssi.dk/Sundhedsdataogit/Indberetning%20og%20patientregistrering/SEI/Patologi.aspx. Accessed November 2013
Dugue PA, Lynge E, Bjerregaard B, Rebolj M (2012) Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 54:266–269. doi:10.1016/j.ypmed.2012.01.012
Danske Regioner (2012) Økonomisk vejledning 2008, 2010, 2011 and 2012. http://www.regioner.dk/økonomi/økonomisk+vejledning/baggrundsmappe2007og2008/regionernes+bidrag+til+patobanken+i+2008. Accessed November 2013
Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M (2001) Age standardization of rates: A new WHO standard. http://www.who.int/healthinfo/paper31.pdf. Accessed May 2013
R Development Core Team (2012) R: A language and environment for statistical computing. Auckland: R Foundation for Statistical Computing. Vienna, Austria. http://www.R-project.org. Accessed October 2013
Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F (2014) 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111:965–969. doi:10.1038/bjc.2014.362
Fujiwara K, Monk B, Devouassoux-Shisheboran M (2014) Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep 16:416. doi:10.1007/s11912-014-0416-y
Nygard M, Hansen BT, Dillner J et al (2014) Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 9:e88323. doi:10.1371/journal.pone.0088323
Foley G, Alston R, Geraci M, Brabin L, Kitchener H, Birch J (2011) Increasing rates of cervical cancer in young women in England: an analysis of national data 1982–2006. Br J Cancer 105:177–184. doi:10.1038/bjc.2011.196
Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044
Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB (2012) Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health 12:992. doi:10.1186/1471-2458-12-992
Dillner J (2000) Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 19:7–23
Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F (2013) Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 49:3262–3273. doi:10.1016/j.ejca.2013.04.024
Bray F, Carstensen B, Moller H et al (2005) Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14:2191–2199
Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C (2013) Outcomes in cervical screening using various cytology technologies: what’s age got to do with it? Eur J Cancer Prev 22:367–373. doi:10.1097/CEJ.0b013e328359cbe0
Rask J, Lynge E, Franzmann M et al (2014) Impact of technology on cytology outcome in cervical cancer screening of young and older women. Int J Cancer 134:2168–2179. doi:10.1002/ijc.28532
Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111:167–177. doi:10.1097/01.AOG.0000296488.85807.b3
Katki HA, Kinney WK, Fetterman B et al (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12:663–672. doi:10.1016/S1470-2045(11)70145-0
Nielsen SL, Daugbjerg SB, Gimbel H, Settnes A (2011) Use of vaginal hysterectomy in Denmark: rates, indications and patient characteristics. Acta Obstet Gynecol Scand 90:978–984. doi:10.1111/j.1600-0412.2011.01199.x
Domingo S, Pellicer A (2009) Overview of current trends in hysterectomy. Expert Rev Obstet Gynecol 4 (6): 673–85. doi:10.1586/eog.09.51. http://www.medscape.com/viewarticle/712569. Accessed August 2014
Lam JU, Lynge E, Njor SH, Rebolj M (2015) Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol Mar 24:1–8. doi:10.3109/0284186X.2015.1016625
Acknowledgments
The study was supported by the Mermaid project (MERMAID II).
Conflict of interest
Birgitte Baldur-Felskov and Christian Munk received travel and speaker’s fees from Sanofi Pasteur MSD. Benny Kirchner has been on the advisory board and received travel fees from GlaxoSmithKline. Jette Junge received advisory board fees from Sanofi Pasteur MSD and consultant fees from Merck. Susanne K. Kjaer received advisory board, speaker’s fees and unrestricted research grants through her institution from Sanofi Pasteur MSD and Merck. Thor Schütt Svane Nielsen, and Christian Dehlendorff report no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all the data and had final responsibility for the decision to submit for publication.
Rights and permissions
About this article
Cite this article
Baldur-Felskov, B., Munk, C., Nielsen, T.S.S. et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control 26, 1105–1116 (2015). https://doi.org/10.1007/s10552-015-0603-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-015-0603-7